Albireo Pharma, Inc.
ALBODelisted Mar 2, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001322505
Albireo Pharma, Inc. was delisted on Mar 2, 2023; its insiders filed their last Form 4 on Mar 3, 2023; 96 institutions reported holding it in 13F filings for Q4 2022, worth $401.7M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 96
- Q4 2022, −12 vs. previous quarter
- 13F value
- $401.7M
- Reported value at the end of Q4 2022
- Superinvestors holding
- 0
- At the end of Q4 2022
Superinvestors holding ALBO, Q4 2022
No superinvestor reported holding ALBO at the end of Q4 2022.
Latest insider trades
Open-market purchases and sales by Albireo Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 23, 2023 (view filing) | Jan 23 | Same day | Stephenson PamelaChief Commercial Officer | SSale | −102 | $43.80 | −$4.47K | −0.2%42.8K after | |
| Jan 23, 2023 (view filing) | Jan 23 | Same day | Graham MichelleChief Human Resources Officer | SSale | −102 | $43.80 | −$4.47K | −0.4%24.5K after | |
| Jan 23, 2023 (view filing) | Jan 23 | Same day | Mattsson JanChief Scientific Officer | SSale | −197 | $43.80 | −$8.63K | −0.4%54.5K after | |
| Jan 23, 2023 (view filing) | Jan 23 | Same day | Harford Simon N.R.CFO and Treasurer | SSale | −102 | $43.80 | −$4.47K | −0.3%32.7K after | |
| Jan 23, 2023 (view filing) | Jan 23 | Same day | Duncan JasonChief Legal Officer and GC | SSale | −228 | $43.80 | −$9.99K | −1.6%14.1K after | |
| Jan 23, 2023 (view filing) | Jan 23 | Same day | Cooper Ronald Harold WilfredPresident and CEO | SSale | −1.06K | $43.80 | −$46.3K | −1.8%57.4K after | |
| Jan 23, 2023 (view filing) | Jan 23 | Same day | Carter Martha J.Chief Regulatory Officer | SSale | −120 | $43.80 | −$5.26K | −0.8%14.5K after | |
| Jan 20, 2023 (view filing) | Jan 19 | 1 day | Stephenson PamelaChief Commercial Officer | SSale | −1.77K | $43.90 | −$77.9K | −4.0%42.9K after | |
| Jan 20, 2023 (view filing) | Jan 19 | 1 day | Carter Martha J.Chief Regulatory Officer | SSale | −938 | $43.90 | −$41.2K | −6.0%14.6K after | |
| Jan 20, 2023 (view filing) | Jan 19 | 1 day | Duncan JasonChief Legal Officer and GC | SSale | −938 | $43.90 | −$41.2K | −6.1%14.4K after |
Top 10 13F holders, Q4 2022
The largest institutional positions in Albireo Pharma, Inc. at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 1,956,488 | $42.3M | 0.12% | −301,636−13.4% | Reduced |
| Perceptive Advisors LLC | 1,757,160 | $38.0M | 1.09% | −602,979−25.5% | Reduced |
| Deep Track Capital, LP | 1,704,000 | $36.8M | 1.61% | +593,376+53.4% | Added |
| Chicago Capital, LLC | 1,362,484 | $29.4M | 1.63% | +242,710+21.7% | Added |
| BlackRock Inc. | 1,344,897 | $29.1M | 0.00% | +129,491+10.7% | Added |
| Vanguard Group Inc | 948,532 | $20.5M | 0.00% | +31,052+3.4% | Added |
| Franklin Resources Inc | 925,070 | $20.0M | 0.01% | −2340.0% | Reduced |
| ArrowMark Colorado Holdings LLC | 786,664 | $17.0M | 0.20% | −4,585−0.6% | Reduced |
| GW&K Investment Management, LLC | 634,701 | $13.7M | 0.14% | −9,091−1.4% | Reduced |
| Decheng Capital Management III (Cayman), LLC | 623,342 | $13.5M | 5.04% | 00.0% | Unchanged |